PI
CPRX

Putnam Investments’s Catalyst Pharmaceutical CPRX Stock Holding History

Putnam Investments’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$445K Sell
26,498
-3,485
-12% -$47.6K ﹤0.01% 960
2023
Q3 		$351K Sell
29,983
-254
-0.8% -$3.4K ﹤0.01% 1019
2023
Q2 		$406K Buy
30,237
+5,151
+21% +$74.1K ﹤0.01% 976
2023
Q1 		$416K Sell
25,086
-1,038
-4% -$17.1K ﹤0.01% 980
2022
Q4 		$486K Sell
26,124
-14
-0.1% -$216 ﹤0.01% 930
2022
Q3 		$335K Buy
+26,138
New +$310K ﹤0.01% 1047

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Putnam Investments's CPRX Position: Q4 2023 in Review

Putnam Investments reduced its Catalyst Pharmaceutical (CPRX) stake by 12% in Q4 2023, selling an estimated $47.6K and leaving 26,498 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #960.

Putnam Investments first reported a position in CPRX in Q3 2022 and has held it in 6 quarters since. The position peaked at $486K in Q4 2022. 259 funds tracked by Wall St. Rank hold CPRX as of Q4 2023.

  • Putnam Investments held 26,498 shares of Catalyst Pharmaceutical worth $445K as of Q4 2023.
  • Putnam Investments sold 3,485 Catalyst Pharmaceutical shares in Q4 2023, an estimated $47.6K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #960 holding.
  • Putnam Investments first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 6 quarters since.
  • Putnam Investments's Catalyst Pharmaceutical position peaked at $486K in Q4 2022.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.